Results 51 to 60 of about 37,893 (278)

Oncolytic virus therapy for cancer

Oncolytic Virotherapy, 2013
The use of oncolytic viruses to treat cancer is based on the selection of tropic tumor viruses or the generation of replication selective vectors that can either directly kill infected tumor cells or increase their susceptibility to cell death and apoptosis through additional exposure to radiation or chemotherapy.
Joe, Goldufsky, Shanthi, Sivendran, Sara, Harcharik, Michael, Pan, Sebastian, Bernardo, Richard H, Stern, Philip, Friedlander, Carl E, Ruby, Yvonne, Saenger, Howard L, Kaufman   +9 more
openaire   +3 more sources

Using Cystine Knot Proteins as a Novel Approach to Retarget Oncolytic Measles Virus. [PDF]

, 2017
Modified measles virus (MV) has effective oncolytic activity preclinically and is currently being investigated in clinical trials for various types of cancer. We investigated the use of cystine knot proteins (CKPs) to direct MV activity.
Lal, Sangeet, Raffel, Corey
core   +2 more sources

A dsRNA Viral Transcriptional Regulator Evades Innate Immunity by Hijacking Host CoTranscription Factor DHX9

Advanced Science, EarlyView.
This study identifies a new viral mechanism by a viral protein σ3 that functions as a vTR to suppress NF‐κB gene expression via its direct interaction with the host helicase DHX9. Through their interaction, σ3 not only impairs the initial recruitment of Pol II but also affects Pol II pause‐release and ultimately suppresses NF‐κB gene expression ...
Xueyang Pang, Shiyu Liu, Yixiao Zhu, Meleana M. Hinchman, Nan Qiao, Xuejun Li, Weiqian Dai, Yingying Tong, Man Xing, Jiling Ren, John S. L. Parker, Yingying Guo, Dongming Zhou   +12 more
wiley   +1 more source

Lung cancer and oncolytic virotherapy——enemy's enemy

Translational Oncology, 2023
Lung cancer is one of the malignant tumors that seriously threaten human health worldwide, while the covid-19 virus has become people's nightmare after the coronavirus pandemic. There are too many similarities between cancer cells and viruses, one of the
Zhang Li, Zhang Feiyue, Li Gaofeng, Liang Haifeng   +3 more
doaj   +1 more source

Logic‐Gated HSV‐TK/GCV Suicide Gene Circuit for Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
The BRAS comprises two modular genetic components driven by distinct tumor‐specific promoters and a failsafe layer with the NOT gate. This multi‐input logic gate circuit enables precise, specific expression of HSV‐TK in breast cancer cells with hardly expression in normal cell and effectively inhibits tumor growth in a triple‐negative breast cancer ...
Shasha Tang, Yuan Fang, Lingli Jin, Dongyang Liu, Yicheng Liu, Ruijia Zheng, Liyun Yong, Xin Wu, Longliang Qiao, Meiyan Wang, Fengfeng Cai   +10 more
wiley   +1 more source

Oncolytic herpes simplex virus and immunotherapy [PDF]

BMC Immunology, 2018
Oncolytic viruses have been proposed to be employed as a potential treatment of cancer. Well targeted, they will serve the purpose of cracking tumor cells without causing damage to normal cells. In this category of oncolytic viral drugs human pathogens herpes simplex virus (HSV) is especially suitable for the cause. Although most viral infection causes
Wenqing Ma, Hongbin He, Hongmei Wang
openaire   +3 more sources

Advances in cell-based delivery of oncolytic viruses as therapy for lung cancer

Molecular Therapy: Oncology
Lung cancer’s intractability is enhanced by its frequent resistance to (chemo)therapy and often high relapse rates that make it the leading cause of cancer death worldwide.
Giti Esmail Nia, Elahe Nikpayam, Molood Farrokhi, Azam Bolhassani, Ralph Meuwissen   +4 more
doaj   +1 more source

Repeated dosing improves oncolytic rhabdovirus therapy in mice via interactions with intravascular monocytes

Communications Biology, 2022
A secondary (but not primary) dose of the oncolytic virus, VSV, is captured by monocytes and promotes CD8 + T cell recruitment, thereby revealing a mechanism underlying the clinical benefit of repeat dosing in oncolytic virus therapy.
Victor Naumenko, Jahanara Rajwani, Madison Turk, Chunfen Zhang, Mandy Tse, Rachelle P. Davis, Daesun Kim, Andrea Rakic, Himika Dastidar, Shinia Van, Laura K. Mah, Esha K. Kaul, Vladimir P. Chekhonin, Douglas J. Mahoney, Craig N. Jenne   +14 more
doaj   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Survivin a radiogenetic promoter for glioblastoma viral gene therapy independently from CArG motifs [PDF]

, 2017
BACKGROUND: Radiogenetic therapy is a novel approach in the treatment of cancer, which employs genetic modification to alter the sensitivity of tumor cells to the effect of applied radiation.
Arafat WO, Arafat WO, Datta R, Deb P, Fiveash JB, Hsu H, Kanzawa T, Kawakami Y, Kufe D, Nandi S, Nenoi M, Nieder C, Pinsker M, Rosenfeld ME, Sonabend AM, Tsai‐Morris CH, Weichselbaum RR   +16 more
core   +2 more sources